Cipla partners with MSN Laboratories for marketing and distribution of generic Xeloda® (Capecitabine Tabs 150mg and 500mg)

Cipla USA, Inc., (“Cipla”) a subsidiary of Cipla Limited, today announced that it has secured rights from MSN Laboratories Private Limited to market & distribute Capecitabine 150mg and 500mg tablets in the United States of America. The product is available immediately.

Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100mg, 150mg, 200mg, 300mg)

Cipla Receives Final Approval for Generic Voltaren® Gel (Diclofenac Sodium Topical Gel, 1%)

A Rare Treat For Andries Meyer Seniors

Cipla Foundation – Sha’p Left wins Vision 2030 Healthcare Award

Cipla Gives Flight To Its Promise Of ‘Caring For Life’ In The SPAR Women’s Challenge

CFO Perspectives: In Conversation With Kedar Upadhye

Cipla Receives Final Approval for Generic Depo-Testosterone® (Testosterone Cypionate for Injection 100mg/ml and 200mg/ml)

Cipla Receives Final Approval for Generic Sustiva® (Efavirenz Tablets 600mg)

Cipla Receives Final Approval for Generic Sustiva® (Efavirenz Tablets 600mg)

Cipla Limited, today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz Tablets 600mg from the United States Food and Drug Administration (US FDA).